Description
Graham Lumsden, chief executive of Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) runs Proactive through the successful completion of a phase III clinical trial of their next-generation antibiotic, Iclaprim.The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).
Tags
iclaprim graham lumsden motif bio